FindTrial
Sign In

Applicatioin of Gata-3 immunocytochemistry in fine needle aspiration smear of axillary lymph nodes of breast cancer patients

Application of Gata-3 immunocytochemistry in situ combined with fine needle aspiration cytology in the diagnosis metastasis of axillary lymph node in breast cancer patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200067220
Enrollment
Unknown
Registered
2022-12-29
Start date
2022-07-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Gold Standard:1. Histopathology of axillary lymph node from sugical specimen showed metastasis
2. EMA immunocytochemistry in situ on the fine needle aspiration smear showed metastasis of tumor.
Index test:Gata-3 immunocytochemistry in situ for detection (Fujian Maixin Technology Co.,Ltd.)

Sponsors

The First Affiliated Hospital, University of South China
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
30 Years to 73 Years

Inclusion criteria

Inclusion criteria: 1. Patients with breast cancer initial confirmed by core needle biopsy; 2. Perform fine needle aspiration cytology of axillary lymph node.

Exclusion criteria

Exclusion criteria: The follow-up resection operation was not finished in the Affiliated First Hospital, University of South China.

Design outcomes

Primary

MeasureTime frame
Gata-3 immunocytochemistry;—

Countries

China

Contacts

Public ContactLan Zhihua

The First Affiliated Hospital, University of South China

lannanzhihua@163.com+86 157 7346 8529

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026